TAKEDA PHARMA A/S: Financial statements 2024
CVR: 16406899
Source: annual report 2024, Danish Business Authority
01/04/2023 – 31/03/2024
TAKEDA PHARMA A/S (CVR 16406899) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 1,118,710,000 and a net result of DKK 261,222,000 compared with DKK 13,573,000 the year before. That is an increase of 5.4% compared with the year before. The profit margin was 23.4%. Equity in the 2024 report amounted to DKK 355,951,000. The solvency ratio was 61.1%. The company had 68 employees in the financial year.
- Revenue
- DKK 1,118,710,000
- Gross Profit
- DKK 437,703,000
- Profit/Loss
- DKK 261,222,000
- Equity
- DKK 355,951,000
- Total Assets
- DKK 582,370,000
- Employees
- 68
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 1.1B | 437.7M | 261.2M | 356M | 68 |
| 2023 | 1.1B | 120.6M | 13.6M | 94.9M | 70 |
| 2022 | 910.1M | 154M | 31.8M | 81.2M | 180 |
| 2021 | 1.9B | 1.1B | 667.7M | 1B | 174 |
| 2020 | 1.6B | 3.2B | 2.7B | 2.7B | 179 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
TAKEDA PHARMA A/S has won the tender "Amgros 2025 1.1211.b" issued by Amgros I/S worth 14,600,000 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2025 1.700.a" issued by Amgros I/S worth 313,301,544 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2025 1.1309.b" issued by Amgros I/S worth 10,000,000 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2025 1.201.a" issued by Amgros I/S worth 149,993,922 DKK.
As of August 28, 2024, Koki Sato has joined the board of directors of TAKEDA PHARMA A/S.
As of August 28, 2024, Vatroslav Mateljic has left the board of directors of TAKEDA PHARMA A/S.
TAKEDA PHARMA A/S has won the tender "Amgros 2024 1.1101.a" issued by Amgros I/S worth 10,513,574 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2024 1.482.b" issued by Amgros I/S worth 28,300,000 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2024 1.480.b" issued by Amgros I/S worth 202,999,999 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2024 1.481.b" issued by Amgros I/S worth 65,310,000 DKK.
About TAKEDA PHARMA A/S
TAKEDA PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1984. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named NYCOMED DANMARK ApS and NYCOMED DANMARK A/S. The management consists of Enor Cerimagic. The board consists of Koki Sato (chair), Enor Cerimagic, Jesper Lindahl and Malene Kelstrup. The company is owned by Takeda Pharmaceuticals International AG. The company has 79 employees (2026). In 2026, the company reported revenue of DKK 1,112,753,000 and a net result of DKK 88,641,000 compared with DKK 12,162,000 the year before. Equity in the 2026 report amounted to DKK 456,501,000.